EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting Microglial Transcriptional Reprogramming as a Therapy Strategy for Alzheimer's Disease

Byungwook Kim iD, Selena S Wang iD, Justin R Kim iD, Jungsu Kim iD

BioEssays · 2026-10 · 48 (10)

DOI: 10.1002/bies.70186 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift BioEssays, online erschienen am 29.09.2026. Verfasst von Byungwook Kim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical & Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Microglia, Cellular Reprogramming. Die Arbeit nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, Alzheimer's Association, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent human genetic studies revealed that Alzheimer's disease risk loci are enriched in genes expressed in myeloid cells, including microglia, the brain's resident immune cells. Notably, several risk‐associated genes, such as SPI1 and MEF2C , encode transcription factors (TFs) that control critical microglial functions, including phagocytosis, inflammatory responses, and neurotrophic support. The objective of this article is to review the recent progress in understanding these TFs and evaluate them as therapeutic targets rather than as markers of microglial state. We examine the genetic evidence implicating PU.1, MEF2C, IRF8, and BHLHE40/41, the in vivo evidence from animal models, the transcriptional network these factors regulate, and the barriers to clinical translation. Because these TFs orchestrate broad gene expression networks by regulating multiple disease‐relevant downstream partners, targeting their expression level or activity could achieve greater therapeutic efficacy than targeting single genes, provided that the dose and disease stage of modulation are carefully considered.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseMicrogliaCellular ReprogrammingHumansAnimalsProto-Oncogene Protein Spi-1Transcription FactorsTrans-ActivatorsMEF2 Transcription FactorsInterferon Regulatory Factor-8Transcription, GeneticGene Expression RegulationInterferon Regulatory Factors

Stichwörter der Autor:innen

alzheimer's diseaseamyloidirf8mef2cmicroglianeuroinflammationphagocytosispu.1 transcription factorspi1transcription factor

Substanzen

Proto-Oncogene Protein Spi-1Transcription FactorsTrans-ActivatorsMEF2 Transcription FactorsInterferon Regulatory Factor-8Interferon Regulatory Factors

Autor:innen und Institutionen

  • Department of Medical & Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Stark Neuroscience Research Institute, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Medical Neuroscience Graduate Program, Indiana University School of Medicine, Indianapolis, Indiana, USA.

ORCID-Profile: Byungwook Kim, Selena S Wang, Justin R Kim, Jungsu Kim

Förderung

  • NIA NIH HHS
  • Alzheimer's Association
  • NIGMS NIH HHS
  • National Science Foundation

Zitieren

APA

Kim, B., Wang, S. S., Kim, J. R., & Kim, J. (2026). Targeting Microglial Transcriptional Reprogramming as a Therapy Strategy for Alzheimer's Disease. BioEssays, 48(10). https://doi.org/10.1002/bies.70186

Vancouver

Kim B, Wang SS, Kim JR, Kim J. Targeting Microglial Transcriptional Reprogramming as a Therapy Strategy for Alzheimer's Disease. BioEssays. 2026;48(10). doi:10.1002/bies.70186

BibTeX
@article{Kim2026,
  author = {Kim, Byungwook and Wang, Selena S and Kim, Justin R and Kim, Jungsu},
  title = {Targeting Microglial Transcriptional Reprogramming as a Therapy Strategy for Alzheimer's Disease},
  journal = {BioEssays},
  year = {2026},
  volume = {48},
  number = {10},
  doi = {10.1002/bies.70186}
}
Kostenlos starten →